 Underuse of innovative medicines in Germany: A justification for government intervention?Afschin Gandjour Health Policy, 2018, vol. 122, issue 12, 1283-1286 Abstract: The German market for innovative medicines is characterized by simultaneous underuse and overuse. In order to address these deficits and improve decision making by physicians, the German parliament recently passed a law which mandates implementing reimbursement decisions on innovative medicines in the prescription software for physicians. This article discusses the political process leading to the law as well as its rationale in view of economic theory. Based on the considerably larger extent of underuse than overuse of innovative medicines in Germany this article predicts that the law will lead to an increase in sales by the pharmaceutical industry. It argues that legislation to increase prescription rates through information technology is questionable in a market where competitive forces should prevail. The correct approach, in line with economic theory, is either to improve information availability for patients or change existing regulation in the case of government failure. The latter may include revoking penalties for physician prescriptions and imposing prescription exclusions. Keywords: Underuse; Medicines; Market failure; Regulation; Information technology (search for similar items in EconPapers) Downloads: (external link) Related works: Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text Persistent link: https://EconPapers.repec.org/RePEc:eee:hepoli:v:122:y:2018:i:12:p:1283-1286 DOI: 10.1016/j.healthpol.2018.08.009 Access Statistics for this article Health Policy is currently edited by Katrien Kesteloot, Mia Defever and Irina Cleemput More articles in Health Policy from Elsevier |
Is your work missing from RePEc? Here is how to contribute.
Questions or problems? Check the EconPapers FAQ or send mail to .
EconPapers is hosted by the
School of Business at Örebro University.